Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling by Sato-Matsubara, M et al.
Fibroblast growth factor 2 (FGF2) regulates cytoglobin
expression and activation of human hepatic stellate cells via
JNK signaling
Received for publication,May 2, 2017, and in revised form, September 11, 2017 Published, Papers in Press, September 15, 2017, DOI 10.1074/jbc.M117.793794
Misako Sato-Matsubara‡§, TsutomuMatsubara¶, Atsuko Daikoku‡, Yoshinori Okina‡, Lisa Longato,
Krista Rombouts, Le Thi Thanh Thuy‡, Jun Adachi**, Takeshi Tomonaga**, Kazuo Ikeda¶, Katsutoshi Yoshizato§,
Massimo Pinzani, and Norifumi Kawada‡1
From the ‡Department of Hepatology, §Endowed Laboratory of Synthetic Biology, and ¶Department of Anatomy and Regenerative
Biology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan, the Regenerative Medicine and Fibrosis
Group, Institute for Liver and Digestive Health, University College London, Royal Free, London NW3 2PF, United Kingdom, and the
**Laboratory of Proteome Research, Proteome Research Center, National Institute of Biomedical Innovation,
Osaka 567-0085, Japan
Edited by Xiao-Fan Wang
Cytoglobin (CYGB) belongs to the mammalian globin family
and is exclusively expressed in hepatic stellate cells (HSCs) in
the liver. In addition to its gas-binding ability, CYGB is relevant
to hepatic inflammation, fibrosis, and cancer because of its anti-
oxidative properties; however, the regulation of CYGB gene
expression remains unknown. Here, we sought to identify fac-
tors that induce CYGB expression in HSCs and to clarify the
molecular mechanism involved. We used the human HSC cell
line HHSteC and primary human HSCs isolated from intact
human liver tissues. In HHSteC cells, treatment with a culture
supplement solution that included fibroblast growth factor 2
(FGF2) increasedCYGB expressionwith concomitant and time-
dependent -smooth muscle actin (SMA) down-regulation.
We found that FGF2 is a key factor in inducing the alteration in
both CYGB and SMA expression in HHSteCs and primary
HSCs and that FGF2 triggered the rapid phosphorylation of
both c-Jun N-terminal kinase (JNK) and c-JUN. Both the JNK
inhibitor PS600125 and transfection of c-JUN–targeting siRNA
abrogated FGF2-mediated CYGB induction, and conversely,
c-JUN overexpression induced CYGB and reduced SMA
expression. Chromatin immunoprecipitation analyses revealed
that upon FGF2 stimulation, phospho-c-JUN bound to its con-
sensus motif (5-TGA(C/G)TCA), located 218 to 222 bases
from the transcription initiation site in the CYGB promoter. Of
note, in bile duct–ligated mice, FGF2 administration amelio-
rated liver fibrosis and significantly reduced HSC activation. In
conclusion, FGF2 triggers CYGB gene expression and deactiva-
tion of myofibroblastic human HSCs, indicating that FGF2 has
therapeutic potential for managing liver fibrosis.
Liver fibrosis is characterized by an excessive accumulation
of extracellular matrix (ECM)2 components in hepatic tissue.
Cirrhosis results in portal hypertension and liver failure and is
associated with an increased risk of hepatocellular carcinoma
(1). The discovery of newdrugs targeting hepatitis viruses B and
C is anticipated to dramatically decrease the number of patients
with virus-related chronic liver disease (CLD) (2). In contrast,
the prevalence of nonalcoholic fatty liver diseases has
increased, and these are anticipated to become a leading cause
of CLD (3). Regardless of the background etiologies, CLD-re-
lated liver fibrosis is a deadly diseaseworldwide (1); however, no
Food and Drug Administration-approved anti-fibrotic drugs
are currently clinically available (4).
Hepatic stellate cells (HSCs) are a dominant contributor to
liver fibrosis, regardless of the underlying disease etiology (5).
In the healthy liver, quiescent HSCs reside in the space of Disse
between hepatocytes and sinusoidal endothelial cells (6). In
response to liver injury, HSCs undergo progressive activation,
transdifferentiating into collagen-producing myofibroblast-
like cells and acquiring contractile properties (7, 8). During the
activation process, HSCs express -smooth muscle actin
(SMA) and synthesize fibrillar ECM, specifically type I and III
collagen (COL I and III) (9). ActivatedHSCs also secrete growth
factors and pro-fibrotic cytokines, including transforming
growth factor-1 (TGF-1) and platelet-derived growth factor
(PDGF), to stimulate HSC activation in an autocrinemanner to
further produceECM(10, 11).However, experimental and clin-
ical studies have revealed that the regression of hepatic fibrosis
occurs following curative therapy of underlying liver diseases
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(12–14). Thus, strategies to reduce HSC activation, i.e. deacti-
vation of HSCs, or to induce reversion to a quiescence-like
phenotype could represent effective anti-fibrotic treatments
(15, 16).
We identified a protein, originally named Stellate cell activa-
tion-associated protein (STAP), from rat cultured HSCs (17)
that is currently referred to as cytoglobin (CYGB) (18). CYGB is
the fourthmember of the vertebrate globin superfamily, and its
sequence is highly conserved among species (18). CYGB has
characteristic properties of a heme protein and exhibits perox-
idase activity that catalyzes hydrogen peroxides and lipid
hydroperoxides (17, 19). CYGB is ubiquitously expressed in all
organs other than the human liver, where it is expressed solely
in HSCs, and its expression is reduced in the livers of patients
with CLD (20, 21). Recently, our laboratory and others have
reported that CYGB plays a protective role both in neuronal
cells and in the liver by reducing reactive oxygen species (ROS)
(22, 23). Furthermore, the administration of human recombi-
nant CYGB was reported to attenuate thioacetamide-induced
liver fibrosis in a rat model (24). However, CYGB expression in
human HSCs and its regulatory mechanism remain largely
unstudied.
Here, we show, for the first time, that fibroblast growth factor
2 (FGF2) is a strong inducer of CYGB in human HSCs via the
activation of c-JUN-terminal kinase (JNK)/c-JUN signaling.
Moreover, FGF2 suppresses SMA expression via the ERK-
signaling pathway. We also show that FGF2 administration
ameliorates liver fibrosis induced by bile duct ligation (BDL) in
mice. Taken together, our study reveals the previously unrec-
ognized FGF2-dependent induction of CYGB gene expression,
which is accompanied by the deactivation of human HSCs and
represents a novel strategy for anti-fibrotic therapy.
Results
Induction of CYGB expression in human hepatic stellate cell
lines
In our first set of experiments, CYGB expression was com-
pared between LX-2 cells, which have been widely used and are
extensively characterized as a human HSC line (25), and the
human HSC line HHSteCs. HHSteCs were established and dis-
tributed by ScienCell Research Laboratories and have been
used as primary humanHSCs (26, 27). LX-2 cells were cultured
in DMEM with 2% FBS. HHSteCs were maintained in SteCM
with 2%FBS and associated supplement solution (1).We con-
firmed that HHSteCs are not an immortalized cell line but are
human normal diploid HSCs because they become senescent
after 15 population doublings under the recommended culture
conditions. As shown in Fig. 1A, CYGB was expressed in
HHSteCs, but not in LX-2 cells, at the protein level. We noted
that therewas hyper-methylation of theCYGBpromoter region
in LX-2 cells but not in HHSteCs, an observation that may
explain the absence of CYGB in LX-2 cells (data not shown).
Supplement solution increased the CYGB protein level and
conversely down-regulated the protein level of SMA, a well-
established myofibroblast and HSC activation marker, in
HHSteCs (Fig. 1B). Along with the protein alterations,
HHSteCs appeared flattened and polygonal in shape with thick
bundles of stress fibers in the absence of supplement solution,
whereas they exhibited a clear boundary with a thinner cell
body and dissolved stress fibers in the presence of supplement
solution (Fig. 1C). The fluorescence intensity of cellular F-actin
was significantly decreased (50%) in supplement solution-
treated HHSteCs compared with that in untreated control cells
(Fig. 1D). HHSteCs retained a high level of CYGB expression
during culture passages (data not shown) and exhibited expres-
sion profiles of well-characterized HSC-associated genes, such
as desmin, neurotrophin-3, retinol-binding protein-1, and lec-
ithin-retinol acyltransferase (supplemental Fig. 1A). LX-2 cells
exhibited relatively low expression levels of desmin and retinol-
binding protein-1 compared with HHSteCs. Thus, HHSteCs
were employed for further analyses in this study.
The CYGB protein level was markedly increased by 560%
and theSMAprotein levelwas decreased to8.5%of the basal
values, and the corresponding mRNA levels were up- and
down-regulated, respectively, by supplement solution (Fig. 1, E
and F). According to these observations, we speculated that
supplement solution might contain substances with the poten-
tial to induce the expression of CYGB and inhibit HSC activa-
tion. To test our hypothesis, supplement solutionwas subjected
to LC-MS/MS analysis. As a result, supplement solution was
found to contain peptide components, such as human FGF2
(supplemental Fig. 2A; a chromatograph of FGF2 peaks),
human insulin, and albumin (frombovine serum; BSA).Human
insulin-like growth factor-1 (IGF-1), which has 48% amino acid
sequence identity with pro-insulin, was also considered a can-
didate. To determine the key factors for CYGB induction in
HHSteCs, the cells were exposed to the basal medium of
SteCM/FBS either alone or in combination with added FGF2 (4
ng/ml), IGF-1 (2 ng/ml), BSA (10g/ml), or insulin (7.5g/ml).
Immunoblot analysis revealed that the combination treatment
of FGF2, IGF-1, andBSAmost faithfully recapitulated the effect
of supplement solution on HHSteCs (CYGB 2-fold increase
and SMA0.5-fold decrease) as measured by the normalized
band intensity (Fig. 1G). In addition, FGF2 alone could recapit-
ulate the supplement solution effect in contrast to IGF-1 and
BSA, each of which alone was unable to promote such an effect.
Thus, we concluded that FGF2 is the major ingredient in sup-
plement solution that induces the “supplement solution effect”
on HHSteCs.
Effects of FGF2 on the expression of CYGB andSMA in
HHSteCs
Immunocytochemical analyses revealed that recombinant
human FGF2 (4 ng/ml) induced the de novo induction of CYGB
and reduction of SMA in a manner similar to the effect of
supplement solution in HHSteCs. Furthermore, a neutralizing
humanFGF2 antibody (2g/ml) counteracted the effect of sup-
plement solution on CYGB and SMA expression according to
both immunostaining and Western blot analysis (Fig. 2, A and
B). The anti-FGF2 antibody also reversed the supplement solu-
tion-induced morphological changes and antagonized the sup-
plement solution-regulated expression of both CYGB and
SMA proteins in HHSteCs in a dose-dependentmanner (sup-
plemental Fig. 3, A and B).
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To examine the level of total FGF receptors (FGFRs) in
HHSteCs, droplet digital PCR analysis was performed to assess
FGFR1, FGFR2, FGFR3, and FGFR4 cDNA copy numbers in
3-day cultured HHSteCs with or without FGF2 (4 ng/ml).
Although the absolute copy number of FGFR1 was the most
abundant among these, only the FGFR2 copy number was sig-
nificantly amplified by FGF2 treatment in HHSteCs (supple-
mental Fig. 3C). Next, we examined the level of FGFR2 pro-
tein and phospho-FGF receptor (p-FGFR; Tyr-653/654) in
HHSteCs. Immunoblot experiments showed that although the
level of total FGFR2 proteinwas unaffected, the level of p-FGFR
was significantly increased in HHSteCs treated with supple-
ment solution or FGF2 (4 ng/ml) compared with the untreated
control; the ratio of p-FGFR/FGFR2wasmarkedly increased by
5.2- and 4.4-fold in HHSteCs treated with supplement solution
and FGF2, respectively. Phosphorylation of c-RAF and MKK4,
downstream signals of FGFR, was also observed (Fig. 2C). In
addition, FGF2 produced a time- and dose-dependent induc-
tion ofCYGBand a reduction ofSMAprotein (Fig. 2,D andE).
For example, inHHSteCs treatedwith 4 ng/ml FGF2, theCYGB
and SMA protein levels were up- and down-regulated by 890
and to 10%, respectively, at 72 h. Furthermore, the time depen-
dence of these effects was confirmed at the mRNA level,
although the alterations ofCYGB andSMAmRNAexpression
were unexpectedly significantly prolonged at 48 h (Fig. 2F).
Both supplement solution and FGF2 also hampered the spon-
taneous induction ofCOLIA1mRNA expression (i.e. untreated
control) in a time-dependent manner (supplemental Fig. 3D).
Figure 1. Effect of supplement solution on CYGB and SMA expression in HHSteCs. A, expression of CYGB in LX-2 cells and HHSteCs. LX-2 cells and
HHSteCs at passage 5 were cultured in DMEM with 2% FBS and SteCM with 2% FBS and supplement solution, respectively, for 72 h and were collected as
precipitates consistingof 106 cells forWesternblotting. CYGBwasexpressedonly inHHSteCs.GAPDHwasusedas a loadingcontrol. RecombinanthumanCYGB
protein was used as a positive control (P.C.). B, levels of CYGB and SMA proteins in HHSteCs stimulated by supplement solution for 72 h. C, phase-contrast
images of HHSteCs cultured with or without supplement solution (S; 1) for 72 h. Scale bars, 100 m. D, F-actin expression visualized with Alexa Fluor
488-conjugated phalloidin using a fluorescence microscope. Scale bars, 100 m. The relative fluorescence intensities of cellular F-actin were quantified in
HHSteCs with or without supplement solution. The data represent themean of four replicates S.D. **, p 0.01 compared with untreated control (unpaired
t test). E, time-dependent expression of CYGB and SMA proteins in HHSteCs stimulated with supplement solution (1). The expression was compared with
the untreated control (last lane;). F, effect of supplement solution on CYGB and SMAmRNA expression in HHSteCs. The data are expressed as the mean
S.D. fromthree independent experiments. *,p0.05 comparedwith0h (one-wayANOVA).G,HHSteCswere treatedwith combinationsof the indicated factors
for 72hand then subjected toWesternblot analysis for CYGBandSMAexpression. The final concentrationsof each substancewere as follows: IGF-1 (4ng/ml);
bovine serumalbumin (10g/ml); insulin (7.5g/ml); and FGF2 (4 ng/ml). * indicates the combination(s) that induce CYGB and down-regulateSMAproteins
compared with the untreated control based on band densities measured using ImageJ software.
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FGF2 initiates CYGB transcription via the JNK pathway
To clarify whether supplement solution and FGF2 regulated
CYGB protein expression at the transcriptional or translational
level, HHSteCs were treated with FGF2 or supplement solution
in the presence of actinomycinDor-amanitin, transcriptional
inhibitors, or G418, a translational inhibitor, compared with
DMSO, a vehicle control. All inhibitors decreased the elevation
of CYGB expression upon FGF2 (4 ng/ml) or supplement solu-
tion treatment, which confirmed that CYGB expression was
regulated at both the transcriptional and translational levels
(Fig. 3A). Furthermore, actinomycin D significantly attenuated
FGF2-induced CYGB mRNA up-regulation in a dose-depen-
dent manner in HHSteCs (Fig. 3B).
Based on the results of dose-response studies for each growth
factor to optimize their concentrations (supplemental Fig. 4A),
HHSteCs were exposed to FGF2 (4 ng/ml), CTGF (80 ng/ml),
HGF (20 ng/ml), PDGF (20 ng/ml), and TGF-1 (5 ng/ml) for
72 h. The CYGB protein level was only increased with FGF2
stimulation. Regarding intracellular signaling pathways, FGF2
triggered the phosphorylation of JNK, ERK, and c-JUN,
whereas HGF, PDGF, and TGF- induced the phosphorylation
of ERK, AKT, and Smad3, respectively, 4 h after the stimulation
of each growth factor (Fig. 3C). FGF2 and supplement solution,
but not TGF-1 (5 ng/ml) treatment, stimulated the phosphor-
ylation of JNK and ERK; the phosphorylation of JNK peaked at
1 h and decreased after 8 h and that of ERK peaked at 4 h and
continued for 24 h (Fig. 3D). To evaluate the pathway required
for CYGB induction by FGF2, the effects of inhibitors against
ERK1/2, JNK, p38, and AKT on the expression of CYGB were
tested. Supplement solution-dependent CYGB induction was
attenuated by SP600125 (180 nM), a JNK inhibitor, but not by
U1026 (20M), anMEK inhibitor, triciribine (260 nM), an AKT
inhibitor, or SB203580 (64 nM), a p38 inhibitor (Fig. 3E). In
addition, upon treatment with 4 ng/ml FGF2, SP600125
induced the reduction of CYGB expression but U1026 failed to
affect the CYGB protein level (Fig. 3F). Taken together, the
FGF2–FGFR2–JNK–c-JUN pathway was elucidated as a pri-
mary pathway in the induction of CYGB in HHSteCs.
FGF2 treatment recruits c-JUN to the proximal region of the
CYGB promoter
An increase in phosphorylated c-JUN and total c-JUN was
observed upon treatment with FGF2 (4 ng/ml) and supplement
solution, but notwithTGF-1 (5 ng/ml), inHHSteCs as early as
1 h after exposure (Fig. 4A). Next, the role of c-JUN in the
expression of CYGB was investigated by transfecting 15.6–500
ng of a pCMFLAG-hcJUN vector into HHSteCs for 72 h. The
c-JUN protein level, as determined by FLAG immunoblotting,
was markedly increased by 125–250 ng of pCMFLAG-hcJUN
vector transfection, resulting in a significant induction of
Figure 2. Effect of FGF2 on CYGB and SMA expression in HHSteCs. A, dual immunofluorescence staining of CYGB (red), SMA (green), and DAPI nuclear
counterstain (blue) in HHSteCs following treatment with supplement solution (1), FGF2 (4 ng/ml), and supplement solution preincubated with anti-FGF2-
neutralizing antibody (2g/ml) for 2 h. Note that both supplement solution and FGF2markedly enhanced CYGB and suppressedSMA expression. The effect
of supplement solution treatment was reversed by anti-FGF2 antibody treatment in HHSteCs. Scale bars, 100 m. B, effect of preincubation of supplement
solution with anti-FGF2 antibody on CYGB and SMA protein expression in HHSteCs. GAPDH was used as a loading control. C, phosphorylation of FGFR
(Tyr-653/654), c-RAF, andMKK4and total FGFR2. c-RAF andMKK4were analyzedbyWesternblotting. HHSteCswere stimulatedwith supplement solution (1)
and4ng/ml FGF2 at the indicated timepoints. GAPDHwasused as a loading control.Right inset, the relative banddensity of phospho-FGFRnormalized to total
FGFR2 comparedwith the control.D and E,Western blottings of CYGB and SMA fromHHSteCs stimulatedwith 4 ng/ml FGF2 at the indicated time points (D)
and with the indicated concentrations of FGF2 for 48 h (E). F, time-dependent expression of CYGB and SMAmRNA in HHSteCs stimulated with 4 ng/ml FGF2.
The data are expressed as the mean S.D. from three independent experiments. ns, not significant; *, p 0.05 compared with 0 h (one-way ANOVA).
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CYGB protein expression by more than 7-fold (Fig. 4B). Inter-
estingly,SMAexpressionwas reducedmarkedly at a high level
of de novo CYGB protein in a specular manner. The induction
of c-JUN led to CYGBmRNA expression, as shown in Fig. 4C.
In contrast, transfection of siRNA directed against c-JUN
significantly decreased the FGF2-induced CYGB mRNA
expression (Fig. 4D). Additionally, the inhibitory effect of
FGF2 on the activation of human HSCs was examined by
using an siRNA system targeted to human CYGB (siCYGB).
The knockdown of CYGB mRNA by siCYGB blunted
the FGF2-triggered down-regulation of SMA mRNA in
HHSteCs. This result demonstrates the direct involvement
of human CYGB in the inhibitory effect of FGF2 on human
HSC activation (Fig. 4E).
Furthermore, we performed ChIP assays followed by quanti-
tative RT-PCR to evaluate the direct binding of c-JUN to the
CYGB promoter region in HHSteCs after 6 h of exposure to
FGF2 (4 ng/ml). The primers were designed by proximity to the
binding of the c-JUN consensus motif (5-TGA(C/G)TCA),
which is located 218 to 222 bases from the transcription
initiation site in the CYGB promoter. ChIP-quantitative PCR
analyses showed that c-JUN associated with chromatin at
distinct sites, with 2.6-fold enrichment in binding to the
anti-phospho-c-JUN antibody versus the untreated control
(primer 1). There was no significant difference in ChIP-
quantitative PCR analysis with the anti-phospho-c-JUN
antibody of the control sites (primer 2; lacking a c-JUN
motif) in the CYGB promoter compared with the untreated
control (Fig. 4F).
FGF2 and supplement solution induce a quiescence-like
phenotype in HHSteCs and human primary-cultured HSCs
Next, we assessed whether FGF2 alters CYGB and SMA
expression in primary-cultured hHSCs. Primary hHSCs were
cultured in either SteCM complete medium or 2% FBS Iscove’s
modified DMEM (IMDM). Primary hHSCs maintained rela-
tively high CYGB expression during the cultivation in IMDM
with supplement solution after the 5th passage (Fig. 5A). In
SteCM-cultured hHSCs without supplement solution, FGF2 (4
ng/ml) increased CYGB and reduced SMA at the protein level
(results from two of four HSC preparations are shown in Fig.
5B), similar to the effect of supplement solution. The relative
Figure 3. Regulatory signaling of CYGB and SMA expression in HHSteCs upon FGF2 and supplement solution stimulation. A, effect of transcription
inhibitors actinomycin D (act-D; 2 g/ml) and -amanitin (AMN; 2 g/ml), as well as a translation inhibitor, G418 (2 g/ml), on CYGB expression under
supplement solution (upper) and4ng/ml FGF2 (lower) stimulation inHHSteCs.B,effect of actinomycinDonCYGBmRNAexpression inHHSteCs stimulatedwith
FGF2 (4 ng/ml). HHSteCs were incubated with the indicated concentrations of actinomycin D for 72 h. *, p 0.05 compared with 0-h (one-way ANOVA). C,
expressionsofCYGBand total andphospho-JNK, ERK, Smad2/3,AKT, andc-JUN inHHSteCswereassayedbyWesternblot analysis after treatmentwithmedium
() or FGF2 (4 ng/ml), CTGF (80 ng/ml), HGF (20 ng/ml), PDGF (20 ng/ml), and TGF-1 (5 ng/ml) at the indicated time points. GAPDH was used as a loading
control.D,HHSteCswere treatedwith supplement solution (1), FGF2 (4 ng/ml), and TGF-1 (5 ng/ml) for the indicated lengths of time (1, 4, 8, and 24 h). Total
levels of phosphorylated JNK (pJNK, T183/Y185), JNK, phosphorylated ERK (pERK), and ERKwere assessed usingWestern blot analysis. E,HHSteCs were treated
with anMEK inhibitor, U1026 (20M), a JNK inhibitor, SP600125 (180 nM), a p38 inhibitor, SB203580 (64 nM), and an AKT inhibitor, triciribine (260 nM) 2 h prior
to the addition of supplement solution (1). Cell lysates were analyzed byWestern blotting with antibodies against CYGB. F,HHSteCs were pretreated with a
JNK inhibitor and an MEK inhibitor at the indicated doses prior to FGF2 (4 ng/ml) treatment. CYGB protein expression disappeared at a high dose of the JNK
inhibitor SP600125 (left) but was unaltered by the MEK inhibitor U1026 (right) in the presence of FGF2 treatment.
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mRNA expression of CYGB and SMA was also increased and
reduced by FGF2, respectively, compared with nontreated
hHSCs. We also examined the effect of supplement solution
and FGF2 on the expression of PPAR, which is a master regu-
lator of adipogenesis and is reported to be suppressed in
cultured–activated human and rat HSCs (28, 29). Supplement
solution and FGF2 significantly increased the relative mRNA
expression of PPAR in hHSCs. Nakatani et al. (30) demon-
strated that secreted protein acidic and rich in cysteine
(SPARC) was co-expressed in PDGF/SMA-positive HSCs in
human liver specimens and was significantly increased during
human chronic hepatitis. We found that the mRNA levels of
SPARC and COLIA1 were significantly reduced by supplement
solution and FGF2 treatment in hHSCs (Fig. 5C).
Additionally, we evaluated the effect of FGF2 on well-known
up-regulated genes in both activated HSCs, such as COLIA1,
COLIA2, SPARC, PDGF-, and the PDGFR- receptor
PDGFR-, and down-regulated genes, such as PPAR and
matrix metalloproteinase-1 (MMP-1), using HHSteCs. FGF2
significantly decreased the mRNA levels of COLIA1, COLIA2,
SPARC, PDGF-, and PDGFR- but significantly increased the
PPAR andMMP-1mRNA levels in HHSteCs (Fig. 5D). Taken
together, FGF2 triggers the induction of a quiescence-like phe-
notype in human HSCs.
Figure4.ActivationofCYGBgene transcriptionbyFGF2via c-JUN inHHSteCs.A,HHSteCswere stimulatedwith supplement solution (1), FGF2 (4ng/ml),
and TGF-1 (5 ng/ml) for the indicated times (1, 4, 8, and24h). Levels of phosphorylated c-JUN (pc-JUN) and total c-JUNwere examinedusingWesternblotting.
B, HHSteCs were transfected with an increasing amount of pCMFLAG-hcJUN (16, 31, 62.5, 125, 250, and 500 ng/ml). An empty vector (EV, 500 ng/ml) was
transfected as a control. Representative relative band densities from c-JUN overexpression of CYGB, SMA, and FLAG proteins are shown in the bar graphs.
Banddensities of CYGB and FLAGwere normalized toGAPDHand comparedwith those of HHSteCs transfectedwith pCMFLAG-hcJUN (16 ng/ml) andwere set
to 1. C, significant increase in CYGB mRNA expression was observed in pCMFLAG-hcJUN-transfected HHSteCs (250 ng/ml) compared with those transfected
with empty vector (250 ng/ml) *, p 0.05 (unpaired t test).D,HHSteCswere transiently transfectedwith siRNA against c-JUN. The decreased c-JUNmRNA level
was confirmed after transfectionwith the specific c-JUN siRNA comparedwith a randomoligonucleotide (negative control). **, p 0.01 (unpaired t test) (left).
Levels of CYGB mRNA were examined following FGF2 (4 ng/ml) treatment for 24 h. The data are expressed as the mean  S.D. from two independent
experiments performed in triplicate. ns, not significant; *, p 0.05 compared with 0 h (one-way ANOVA) (right). CONT, control. E, HHSteCs were transiently
transfected with siRNA against human CYGB. siRNA-transfected HHSteCs were treated with and without FGF2 (4 ng/ml) for 48 h. The decreased CYGBmRNA
level was confirmed after transfection with CYGB siRNA compared with a random oligonucleotide (negative (Neg) control). The level of SMA mRNA was
investigated in siRNA-transfectedHHSteCswith the treatment of FGF2. ns, not significant; *, p 0.05 comparedwith the untreated control (unpaired t test); **,
p  0.01, and ***, p  0.001. F, ChIP analysis of phospho-c-JUN at the CYGB promoter was analyzed by quantitative RT-PCR. Primers were designed at the
c-JUN-bindingmotif (primer 1; containing the TGA(C/G)TCADNA sequence) and non-c-JUN-binding region in the CYGB promoter within 1500 bp upstreamof
the transcriptional initiation site in HHSteCs treatedwith or without FGF2 (4 ng/ml) for 6 h. The untreated control was set as 1, and the result was presented as
relative fold enrichment. The data are expressed as the mean  S.D. from three independent studies. ns, not significant; **, p  0.01 compared with the
untreated control (unpaired t test with Welch’s correction).
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FGF2 treatment attenuates BDL-induced liver fibrosis inmice
Based on the effect of FGF2 on the CYGB expression and
activation status of cultured primary hHSCs and HHSteCs, we
next assessed the potential role of exogenous FGF2 on liver
fibrosis. To this end, mice were subjected to BDL-induced liver
fibrosis and were administered recombinant mouse Fgf2 (60
g/kg) via the tail vein twice per week following 2weeks of BDL
(Fig. 6A). The serum levels of aspartate aminotransferase (ALT)
and alanine transaminase (AST) tended to decrease (albeit not
significantly) with Fgf2 treatment (Fig. 6B). H&E and Sirius red
staining revealed hepatocyte damage with bile duct hyperplasia
and extended fibrosis predominantly around the portal vein
areas of the BDL-control livers, whereas Fgf2 treatment mark-
edly attenuated these manifestations (Fig. 6, C and D). The
quantitative Sirius red-positive areas were significantly
decreased in Fgf2-treated mouse livers compared with control
treatment (Fig. 6D). Both Cygb- and Sma-positive cells were
propagated around portal vein areas in medium-injected BDL
murine livers. Fgf2 administrationmaintainedCygb expression
but markedly suppressed Sma expression around portal vein
areas (Fig. 6E). Immunoblot analysis confirmed the mainte-
nance of Cygb and marked reduction of Sma by Fgf2 admin-
istration, compared with control medium injection, in BDL-
treated murine livers (Fig. 6F). The levels of CygbmRNA were
increased in BDL murine livers compared with those of the
controls, but there were no differences between the medium
and FGF2-injected BDL groups. However, the expression levels
of Sma and ColIa1 mRNA were significantly reduced in
FGF2-treated mouse livers compared with those in the medi-
um-treated mouse livers (Fig. 6G). These observations suggest
that the administration of Fgf2 attenuated BDL-induced liver
fibrosis, in part, by reducing the number of activated HSCs.
Discussion
We have demonstrated that FGF2 is a key modulator of an
activated phenotype of human HSCs by up-regulating CYGB
expression via the JNK/c-JUN pathway. Thus, we have delin-
eated previously unrecognized and temporally controlled cas-
cades that differentially regulate CYGB and activate HSC-re-
lated genes, such as SMA, COL1A1, COL1A2, and SPARC, in
response to FGF2 in human HSCs. We have also revealed that
pharmacological application of FGF2 attenuates the progres-
sion of liver fibrosis in an experimental murine BDL model,
indicating that FGF2 is a candidate anti-fibrotic agent for the
treatment of liver fibrosis.
During liver injury, HSCs undergo sequential events of acti-
vation, including cell proliferation, contractility, matrix degra-
dation, retinoid loss, and cytokine and chemokine release (31),
leading to fibrosis development and the deposition of ECM rich
in type I collagen. During this process, HSCs are exposed to
fibrogenic factors, such as TGF-1, interleukin-1 (IL-1), IL-6,
PDGF, tumor necrosis factor-, and ROS (32), which are
derived from injured hepatocytes, activated endothelial cells,
and Kupffer cells (31, 33). The overproduction of ROS leads to
the depletion of anti-oxidants in the injured liver, and activated
HSCs become more susceptible to oxidative stress because of
their inability to detoxify lipid peroxidation products via
reduced detoxification enzymes, such as glutathione S-trans-
ferases and catalase (34). Thus, the imbalance between the gen-
eration of ROS and the anti-oxidant defense system of cells is
Figure 5. FGF2 enhances CYGB and suppresses SMA expression in human primary HSCs. A, human HSCs were cultured under different conditions, i.e.
IMDMonly, IMDM, 2%FBS, and IMDM, 2%FBSwith supplement solution at the 5th passage. The level ofCYGBwas assessed by quantitative RT-PCR. *, p 0.05;
***, p 0.005; comparedwith the IMDM control (n	 3, one-way ANOVA). B, effect of supplement solution and FGF2 on the CYGB andSMA expression levels
of two individual primary humanHSC (hHSC1 and hHSC2) preparations. C, relativemRNA expression of CYGB,SMA, PPAR, SPARC, and COLIA1was examined
following supplement solution (1) and FGF2 (4 ng/ml) treatment for 5 days in primary hHSCs. The data are expressed as the mean  S.D. from two
independent experiments performed in triplicate. *, p 0.05; **, p 0.001l; ***, p 0.005, ns, not significant, comparedwith the untreated control (unpaired
t test withWelch’s correction).D, expression profiles of genes that are generally up-regulated in activated HSCs: COLIA1, COLIA2, SAPRC, PDGF-, and PDGFR-
in quiescent HSCs; PPAR andMMP-1 in HHSteCs. mRNA expression was assessed after 72 h of treatment with supplement solution (1) and FGF2 (4 ng/ml)
usingquantitativeRT-PCR.Untreatedcellswereusedas representative controls. Thedata areexpressedas themeanS.D. fromtwo independent experiments
performed in triplicate. p 0.05 (n	 3, unpaired t test with Welch’s correction).
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causatively deleterious to the cells. Overall, inducing endoge-
nous CYGB without harming other biological events may be
advantageous when blocking HSC activation during liver
fibrosis.
In this study, we investigated the role of FGF2 in the tran-
scriptional regulation of CYGB in human HSCs. FGFs are a
mediator of fibroblast growth and are widely expressed in var-
ious cell types (35). FGF2 has been considered to be pro-fibrotic
because of its potential chemotactic and mitogenic activities in
HSCs in culture and the observed delay in excisional skin
woundhealing inmice lacking FGF2 (36–38). In contrast, accu-
mulating evidence has suggested that FGF2 is a potent anti-
fibrogenic factor. FGF2 was not required for the generation of
bleomycin-induced lung fibrosis, whereas it was essential for
lung epithelial recovery (39). FGF2was reported to be one of the
key factors in promoting the inactivation of HSCs to a more
quiescent-like phenotype in vitro (40). Finally, Pan et al. (41)
showed an opposing function between low- and high-molecu-
lar-weight FGF2, and the administration of low-molecular-
weight FGF2 effectively reversed liver fibrosis. In addition to
the previous study results obtained using rodent models and
cells, we revealed here that FGF2 is a key molecule for CYGB
Figure 6. Fgf2 ameliorates liver fibrosis in amouse BDLmodel. A, schematic illustration of the BDL-induced liver fibrosis model. Two weeks after surgery,
mice were intravenously injected twice a week with IMDM (medium, control vehicle) and 60 g/kg recombinant mouse Fgf2 in IMDM, and then were
euthanized at day 21 for further analyses. B, serum levels of ALT andAST of sham-operatedmice (; n	 3), sham-operated andmedium (IMDM)-injectedmice
(n	 3), sham-operated and IMDM/Fgf2-injectedmice (n	 3), BDL-operated and IMDM-injectedmice (n	 6), and BDL-operated and IMDM/Fgf2-treatedmice
(n	 6)were examined. Theopen columns and closed columns indicate sham-operated andbile duct–ligatedmice, respectively.ns, not significant.C andD, liver
fibrosis was evaluated by H&E (HE) staining (C) and Sirius red staining (D) in liver sections of BDLmedium (medium) and BDL-Fgf2 (Fgf2)–treatedmice. P, portal
triad; C, central vein, Scale bars, 200 m. The graphs show the quantification of Sirius red-stained and SMA-positive areas in the control BDL medium group
versus the BDL-Fgf2–treated group. Note the significant reduction of collagen deposition with Fgf2 treatment. The results are shown as themedian S.E. for
biological replicates (n	 6). Student’s t test, p 0.01. E, immunohistochemistry for Cygb (right) andSma (left) in serial liver sections fromBDL-operatedmice
withmedium (upper) andFgf2 (lower) injections.Magnified viewsof the enclosedarea show that cells stainedpositive for Cygbbutnegative forSma. Scale bar,
100 m (20 magnification). The percentage areas of Cygb and Sma positivity were measured in three random fields at10 magnification. The data are
presented as Mann-Whitney U test analyses as the median S.E. ns, not significant; **, p 0.01 between BDL-Fgf2–treated mice and BDL medium–treated
mice. F, representative bands fromWestern blot analysis of Cygb andSma expression in sham- and BDL-operatedmicewith both control (medium) and Fgf2
injections. CYGB expression was increased with both medium and Fgf2 treatment, whereas Sma expression was significantly reduced in BDL-operated
Fgf2-injectedmice. The relativebanddensities of CygbandSmacomparedwith theBDL-operated control for at least threedifferent animals fromeachgroup
were examined. Gapdh served as a loading control (n	 3 in each group). The data are presented as the mean S.E. for biological replicates (n	 3 for each
group). Unpaired t test,ns, not significant; **,p0.01.G, relativemRNA levels ofCygb,Sma, andColIa1 in liver tissuesof sham-operatedandBDLmice injected
with medium and Fgf2 were analyzed by quantitative RT-PCR. The open columns and closed columns indicate sham-operated and bile duct–ligated mice,
respectively. The data are presented as one-way ANOVA as the median S.E. *, p 0.05.
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induction and for maintaining humanHSCs in a quiescent-like
phenotype.
This study demonstrated that a signaling network orches-
trates the initiation of JNK and c-JUN phosphorylation, result-
ing in the alteration of CYGB expression in HHSteCs upon
FGF2 stimulation. We also discovered direct binding of c-JUN
at the CYGB promoter in proximity to the c-JUN-binding site
upon FGF2 treatment. In human HSCs, our observation sug-
gests that the fine-tuning of FGF2-mediated CYGB expression
is tightly regulated and further deactivates HSCs, as demon-
strated by a marked reduction in SMA expression, a well-
known marker of HSC activation. Previous work from our
group showed that the transient knockdown of Cygb by siRNA
results in increased Sma expression in primary mouse HSCs
(22) and that Sma expression was notably high in HSCs iso-
lated from CYGB knock-out mice (42), implying that CYGB
associates with SMA expression during the activation of
HSCs. Moreover, we observed that overexpression of c-JUN
markedly up-regulated CYGB and down-regulated SMA
expression inHHSteCs (Fig. 4B) and that knockdown of human
CYGB by siCYGB counteracted FGF2-triggered down-regula-
tion of SMA mRNA in HHSteCs (Fig. 4E). Taken together,
these observations indicate the involvement of human CYGB
in the inhibitory effect of FGF2 on human HSC activation,
although the detailed molecular mechanism of this phenome-
non needs to be studied further.
Although the administration of Fgf2 in vivo to BDLmice was
insufficient to induce Cygb expression in the liver (Fig. 6F), this
result could be explained by masking of the pharmacological
action of exogenous murine Fgf2 via the spontaneous and
robust induction of Cygb, which is likely to attenuate murine
HSC activation, a process initiated by the still unidentified
molecularmechanisms (5, 8), and to increase the Cygb-positive
HSC numbers in BDL murine livers. It should be noted that
Fgf2 administrationmaintainedCygb expression around portal
vein areas rich in myofibroblastic HSCs at day 21 but markedly
suppressed Sma expression (Fig. 6E), indicating the contribu-
tion of Fgf2 to sustained expression of Cygb. Our previous and
ongoing studies clearly demonstrated that BDL-induced liver
fibrosis was markedly enhanced in Cygb-deficient mice (43)
and conversely limited in conditional CYGB-transgenic mice,3
demonstrating the anti-fibrotic role of Cygb in themurine liver.
It should also be noted that exogenously administered FGF2
may target other hepatic cells for its anti-fibrotic effects; Pan et
al. (41) demonstrated that the administration of recombinant
low-molecular-weight FGF2 markedly reduced CCl4-induced
liver fibrosis via the suppression of delta-like 1 (Dlk-1) expres-
sion in damaged hepatocytes, resulting in a decreased level of
Dlk-1 protein in the liver and serum to prevent HSC activation.
To understand human pathological conditions, Fgf2-mediated
regulation of HSC activation via Cygb in vivo needs to be fur-
ther validated using various animal models.
In summary, these data revealed that FGF2 is a novel key
inducer of CYGB and a suppressor of SMA, COLIA1, and
COLIA2 in human HSCs. Together with our in vivo results, we
hypothesize that FGF2 is one of the master regulators of HSC
activation. The identification of critical regulatory pathways to
control the activation of myofibroblasts, including HSCs, is
profoundly important for developing a therapeutic strategy for
organ fibrosis. Our molecularly based study of the effect of
FGF2 on human HSCs has led to greater understanding of the
pathogenesis of hepatic fibrogenesis and provided a strategy to
promote the resolution of liver fibrosis.
Experimental procedures
Cell culture
Human hepatic stellate cells, referred to as HHSteCs, were
purchased from ScienCell Research Laboratories (San Diego).
LX-2was acquired from theAmericanTypeCulture Collection
(ATCC, Manassas, VA), and primary hHSCs were obtained
from the Institute for Liver and Digestive Health, Royal Free
Hospital, University College London (London, UK). Cells were
cultured accordingly in the growth medium, listed in supple-
mental Table 1. HHSteCs were passaged when subconfluent in
a humidified atmosphere containing 95% air and 5% CO2 and
were used between passages 3 and 10 for the experiments. Pri-
mary hHSCs were isolated from resected liver wedges and were
obtained from patients undergoing surgery at the Royal Free
Hospital after providing informed consent (EC01.14-RF). Cells
were isolated according to a published protocol (44) with mod-
ifications for the human liver (45). Upon arrival, a portion of the
hHSCs was cultured in SteCM plus 2% FBS with supplement
solution. The pCMFLAG-hcJUN plasmid was provided by
RIKEN BRC through the National Bio-Resource Project of
Ministry of Education, Culture, Sports, Science and Technol-
ogy (MEXT) (Tsukuba, Ibaraki, Japan). In transient transfec-
tion assays, HHSteCs were transfected using Lipofectamine
3000 transfection reagent (Thermo Fisher Scientific,Waltham,
MA) for the pCMFLAG-hcJUN vector and Lipofectamine
RNAiMAX (Thermo Fisher Scientific) for siRNA transfection.
Treatment assays
HHSteCs were seeded at a concentration of 1 105 cells/ml
in SteCM complete medium. The following day, the medium
was changed to 2% FBS/SteCM without supplement solution,
and cells were stimulated with 4 ng/ml recombinant human
basic fibroblast growth factor (FGF2, Wako Pure Chemical
Industries, Ltd., Tokyo, Japan) for 72 h, unless otherwise indi-
cated. Recombinant human TGF-1 (R&D Systems, Minneap-
olis, MN) diluted in sterile 4 mM HCl containing 1 mg/ml BSA
was used as a strong inducer of HSC activation-related genes,
SMA, and collagens. Recombinant human CTGF (46), HGF
(47), and PDGF-BB (38) were purchased from PeproTech Inc.
(Rocky Hill, NJ). An optimal concentration for each cytokine
was determined by using preliminary titrations (supplemental
Fig. 4A). For the neutralizing assay, anti-FGF2/basic FGF anti-
bodies (2g/ml,Millipore, Temecula, CA)were incubatedwith
supplement solution-containing medium for 1 h at 37 °C, and
the mixture was added to the cells for 72 h. The effects of the
following inhibitors of signaling molecules on CYGB and
SMA expression in HHSteCs were examined at their respec-
tive optimal concentrations that were determined from refer-
ences, and as indicated in Fig. 3F: U1026 (MEK inhibitor) (48,3 N. T. T. Hai, N. Q. Dat, and N. Kawada, unpublished data.
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49), triciribine (AKT inhibitor) (50), SB203580 (p38 inhibitor)
(51), and SP600125 (JNK inhibitor) (52), all from Wako Pure
Chemical Industries, Ltd. Actinomycin D,-amanitin (53), and
G418 (54) (Wako Pure Chemical Industries, Ltd.) were used for
transcription and translation inhibition assays. The inhibitors
at the indicated concentrations did not showany toxicity on cell
viability or proliferation.
Western blot analyses
Cells were lysed in RIPA buffer (50mMTris-HCl, pH 7.5, 150
mM NaCl, 1.0% Nonidet P-40, 0.1% SDS, and 0.5% sodium
deoxycholate) containing protease inhibitors (Roche Applied
Science, Basel, Switzerland) and phosphatase inhibitors
(Thermo Fisher Scientific). The cell lysates were dissolved in
SDS sample buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 4%
SDS, 0.5% bromphenol blue, and 10%-mercaptoethanol). Ali-
quots containing 30–40 g of cellular proteins were separated
by 4–10% SDS-PAGE (DRC, Tokyo, Japan) and were trans-
ferred to 0.45-m polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad). Themembranes were incubated overnight at
4 °C with the primary antibodies listed in supplemental Table 2
and were incubated with HRP-conjugated goat anti-mouse or
rabbit secondary antibodies (1:5000, Dako, Agilent Technolo-
gies, Santa Clara, CA). Proteins were visualized using enhanced
chemiluminescence (Thermo Fisher Scientific), and their lumi-
nescence was quantified using a luminescent image analyzer,
LAS-300 (Fujifilm, Tokyo, Japan). The staining intensity of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a loading control.
Quantitative RT-PCR
Cells were lysed in TRIzol reagent (Thermo Fisher Scientific)
using the Direct-zol RNAminiPrep kit (Zymo Research, Irvine,
CA), and cDNA was generated using SuperScript III reverse
transcriptase (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions. Quantitative RT-PCR assays were per-
formed using Fast SYBR Green Master Mix (Thermo Fisher
Scientific) and an Applied Biosystems 7500 real-time PCR sys-
tem (ThermoFisher Scientific) using the primers shown in sup-
plemental Table 3. The relative expression levels were normal-
ized to 18S expression, and fold changes in expression were
calculated using the comparative 2

CT method (55).
ChIP analysis
ChIP assays were carried out using a SimpleCHIP Enzymatic
Chromatin IP kit withmagnetic beads (Cell Signaling Technol-
ogy, Danvers, MA) according to the manufacturer’s instruc-
tions. Briefly, HHSteCs were treated with or without FGF2 (4
ng/ml) for 6 h and were collected with ChIP dilution buffer.
Two percent of the supernatant was saved as the input control.
Five micrograms of phospho-c-JUN (Ser-73) XP rabbit anti-
body (Cell Signaling Technology) was added to the diluted
chromatin and was incubated overnight. Mock immunopre-
cipitation was performed in parallel with normal rabbit IgG.
Quantitative RT-PCR was performed using ChIP DNA. The
data were normalized to that of the input DNA. The primer
sequences are shown in supplemental Table 4. The value of the
untreated control was set at 1. The results are presented as the
relative fold enrichment.
Immunochemical and phalloidin staining
Cells were fixed with 4% paraformaldehyde (Wako Pure
Chemical Industries, Ltd.) and were incubated with polyclonal
rabbit anti-CYGB antibody (1:300, in-house) and/or monoclo-
nal mouse anti-human SMA antibody (1:200, Dako) over-
night. Next, cells were washed and stained with Alexa Fluor
594-conjugated goat anti-rabbit and 488-conjugated goat anti-
mouse IgG antibodies (1:500, Thermo Fisher Scientific). For
F-actin staining, cells were stained with Alexa Fluor 488-conju-
gated phalloidin (Abcam, Cambridge, UK) for 40 min at room
temperature. Cells were counterstainedwith 4,6-diamidino-2-
phenylindole (DAPI, Dojindo Molecular Technologies, Inc.
Tokyo, Japan). The integrated intensity above the threshold of
phalloidin-iFluor 488 in one channel was computed and nor-
malized to the number of nuclei (DAPI staining) measured in
the other channel, thus giving an average staining intensity per
cell using BZ-II analyzer software (Keyence,Osaka, Japan). For-
malin-fixed murine liver tissue sections were antigen-retrieved
and incubated with anti-SMA antibody. Images were cap-
tured using a BZ-X700-All-in-One fluorescence microscope
(Keyence).
Animal studies
BDL was performed on 6–8-week-old male C57BL/6 mice
(Japan SLC, Inc., Shizuoka, Japan). All animal experimentswere
performed in accordance with the Guide for Animal Experi-
ments, approved by the Animal Research Committee of Osaka
City University. Animals were randomly assigned to experi-
mental groups. The surgical procedures were performed under
anesthesia via an intraperitoneal injection of 30 mg/kg body
weight somnopentyl (Kyoritsu Seiyaku Corp., Tokyo, Japan).
Obstructive jaundice was induced by a midline incision in the
abdomen and bile duct exposure followed by double ligation
with 6-0 silk. Two weeks after surgery, recombinant murine
Fgf2 (FGF-basic, PeproTech) at a dose of 60g/kg body weight
was reconstituted in 100 l of IMDM and administered via the
tail vein twice a week. Animals were euthanized 72 h after the
second FGF2 injection. The blood and liver were retrieved for
histochemical, biochemical, and molecular analyses. Animals
that received an equal volume of IMDM or that underwent
sham operation were used as controls (six mice with BDL and
three mice without BDL per group). Excised liver specimens
were fixed in 10% neutral-buffered formalin and were embed-
ded in paraffin. H&E staining was performed for histological
analysis. Sirius red staining (Wako Pure Chemical Industries,
Ltd.) for collagen deposition was performed according to the
standard procedure. Immunohistochemical analysis on paraf-
fin-embedded sections was performed using a polyclonal rabbit
anti-mouse Cygb antibody (1:300, in-house) and a monoclonal
mouse anti-SMA (1:200, DAKO) and stainedwithAlexa Fluor
594-conjugated goat anti-rabbit and 488-conjugated goat anti-
mouse IgG antibodies (1:500, Thermo Fisher Scientific). Nuclei
were counterstained with hematoxylin QS (Vector Laborato-
ries, Inc., Burlingame, CA). The percentage areas of Cygb- and
Sma-staining HSCs measured in three high-power fields at a
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magnification of10 in five different animals from each group
were examined.
Statistics and reproducibility
All experiments, except for the graphs without error bars,
were replicated a minimum of three times. ImageJ analysis was
used to determine the optical densities for Western blot analy-
sis and quantitative analysis of Sirius red staining (National
Institutes of Health, Bethesda). The level of significance was
determined by unpaired t test with Welch’s correction, one-
way ANOVA, or the Mann-Whitney U test (repeated mea-
sures) for differences across experimental groups and was ana-
lyzed with GraphPad Prism6 software. The data are expressed
as themean S.D. ormedian S.E. p values less than 0.05were
considered to indicate statistical significance.
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